Zacks Research Research Analysts Lift Earnings Estimates for GSK plc (NYSE:GSK)

GSK plc (NYSE:GSK) – Equities research analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for GSK in a note issued to investors on Tuesday, June 25th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings per share of $4.47 for the year, up from their previous forecast of $4.41. The consensus estimate for GSK’s current full-year earnings is $4.11 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $1.01 EPS and FY2026 earnings at $4.91 EPS.

Other equities analysts have also recently issued reports about the company. Citigroup upgraded GSK to a “strong-buy” rating in a research note on Monday, June 24th. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. The Goldman Sachs Group began coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price on the stock. Finally, Berenberg Bank upgraded GSK to a “strong-buy” rating in a research note on Thursday, June 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

GSK Stock Performance

Shares of GSK opened at $38.50 on Thursday. The business’s fifty day moving average price is $42.51 and its 200 day moving average price is $41.17. GSK has a 12-month low of $33.67 and a 12-month high of $45.92. The stock has a market capitalization of $79.79 billion, a PE ratio of 13.95, a price-to-earnings-growth ratio of 1.17 and a beta of 0.66. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The firm had revenue of $9.34 billion for the quarter, compared to analysts’ expectations of $8.98 billion.

Institutional Investors Weigh In On GSK

Hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc raised its stake in shares of GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 676 shares in the last quarter. Register Financial Advisors LLC bought a new stake in shares of GSK during the first quarter valued at about $31,000. BKM Wealth Management LLC bought a new stake in shares of GSK during the fourth quarter valued at about $32,000. Richardson Financial Services Inc. bought a new stake in shares of GSK during the fourth quarter valued at about $40,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of GSK during the first quarter valued at about $49,000. 15.74% of the stock is currently owned by institutional investors.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a dividend of $0.3762 per share. This is a boost from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.91%. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s payout ratio is currently 53.26%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.